Can a Pre-Transplant HPV shot shield patients from cancer?
NCT ID NCT03036930
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This phase 2 trial tests whether giving the HPV vaccine (Gardasil 9) to adults before a kidney transplant helps their immune system fight HPV after transplant, when they must take strong anti-rejection drugs. About 51 participants will receive the vaccine and have their immune response measured. The goal is to see if pre-transplant vaccination can provide lasting protection against HPV-related cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
UCSF Medical Center-Mount Zion
San Francisco, California, 94115, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9)
What this could lead to
If it works, this could show that giving the HPV vaccine before a kidney transplant helps protect patients from HPV-related cancers even while they take lifelong anti-rejection drugs.
What could go wrong
This is a small, early-phase trial with only 51 participants and no comparison group, so results may not apply to everyone. The vaccine may not produce strong or lasting immunity in people on immunosuppressants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.